Influence of psychiatric disorders in patients treated with Varenicline
| Autor: | Pedro Juan Rodríguez-Martín, Natalia Fouz Rosón, Cristina Benito-Bernáldez, Virginia Almadana-Pacheco, Teodoro Montemayor-Rubio, Carolina Panadero-Paz |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
media_common.quotation_subject medicine.medical_treatment law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law medicine 030212 general & internal medicine Bipolar disorder Psychiatry Varenicline Depression (differential diagnoses) media_common business.industry Addiction medicine.disease chemistry Schizophrenia Anxiety Smoking cessation medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Tobacco, Smoking Control and Health Education. |
| DOI: | 10.1183/1393003.congress-2017.pa4478 |
| Popis: | Aims: Varenicline is used in smoking cessation. The patients recruited in our unit are not all healthy smokers, but patients from real clinical practice, so some of them have psychiatric conditions. The aims of the study were: -evaluate if treatment effectiveness is influenced by any of these conditions -compare standard vs low dose in these specific groups -evaluate the evolution of psychiatric parameters (HADS scale) Methods: Open-label randomized parallel-group controlled trial with 1-year follow-up, at the Stop-Smoking Clinic of the Virgen Macarena University Hospital in Seville. Patients were randomized either to 1 mg or 0.5 mg (both twice daily during 8 weeks). Results: From the 109 patients previously diagnosed with anxiety and depression disorder, 41,3% stopped smoking vs 49% of those who did not have this condition (p=0,154). There was a tendency to better results with the low dose (44,3% vs 37,5% with the standard dose, p=0,094). The patients with other psychiatric diseases, like bipolar disorder or schizophrenia, had more difficulties to stop smoking than those without these diseases and they were more successful with the low dose, but p values were non significant. The patients with addiction to other drugs had a tendency to quit smoking less than those without drug addiction (34,3% vs 48,2%, p=0,078). Regarding to the evolution of the psychiatric parameters, there was a reduction of more than 50% of the HADS score from the start of the program to the end of the follow-up year. Conclusions: Psychiatric conditions are related to more difficulties to stop smoking and these patients have a tendency to a better response to low doses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|